CHOEP regimen: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 10: | Line 10: | ||
==Regimen== | ==Regimen== | ||
{{chemo|C|Cyclophosphamide}} | |||
{{chemo|H|Doxorubicin (Hydroxydaunomycin)}} | |||
{{chemo|O|Vincristine (Oncovin)}} | |||
{{chemo|E|Etoposide}} | |||
{{chemo|P|Prednisone}} | |||
==Indications== | ==Indications== | ||
Latest revision as of 15:16, 11 March 2015
|
WikiDoc Resources for CHOEP regimen |
|
Articles |
|---|
|
Most recent articles on CHOEP regimen Most cited articles on CHOEP regimen |
|
Media |
|
Powerpoint slides on CHOEP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CHOEP regimen at Clinical Trials.gov Trial results on CHOEP regimen Clinical Trials on CHOEP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CHOEP regimen NICE Guidance on CHOEP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CHOEP regimen Discussion groups on CHOEP regimen Patient Handouts on CHOEP regimen Directions to Hospitals Treating CHOEP regimen Risk calculators and risk factors for CHOEP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CHOEP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: CHOPE; VACOP
Overview
CHOEP regimen refers to an immunochemotherapy regimen consisting of cyclophosphamide, Doxorubicin(hydroxydaunorubicin), Vincristine (Oncovin), Etoposide, Prednisone of non-Hodgkin lymphoma.[1][2]
Regimen
CCyclophosphamide
HDoxorubicin (Hydroxydaunomycin)
OVincristine (Oncovin)
EEtoposide
PPrednisone
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C; et al. (2004). "Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL". Blood. 104 (3): 626–33. doi:10.1182/blood-2003-06-2094. PMID 14982884.